Table 11.
Characteristics of NSCLC commercial specimens used for RT-qPCR assay validation (N = 200).
| Characteristic | n | % | ΔCt (N = 185)a,b |
|
|---|---|---|---|---|
| Median | Range | |||
| NSCLC tumor subtype | N = 200 | |||
| Adenocarcinoma | 118 | 59.0 | 4.9 | 1.7–9.4 |
| Squamous cell carcinoma | 62 | 31.0 | 2.9a | 0.4–8.1a |
| Large cell carcinoma | 18 | 9.0 | 6.2 | 1.1–9.2 |
| Adenosquamous carcinoma | 2 | 1.0 | [4.3]f | [4.3]f |
| Tumor stage c | N = 194d | |||
| I | 52 | 26.8 | 4.3 | 1.2–8.5 |
| II | 72 | 37.1 | 4.6 | 0.4–9.2 |
| III | 59 | 30.4 | 4.2a | 1.1–9.4a |
| IV | 11 | 5.7 | 3.6 | 0.6–8.1 |
| Tumor content, % | N = 200 | |||
| 50–60 | 17 | 8.5 | 4.3 | 2.6–7.9 |
| 65–70 | 36 | 18.0 | 3.9 | 0.4–8.1 |
| 75–80 | 42 | 21.0 | 4.6 | 0.6–8.1 |
| 85–90 | 73 | 36.5 | 4.4e | 0.5–9.4a |
| ≥95 | 32 | 16.0 | 5.9 | 1.3–8.9 |
| Time from biopsy to analysis, mo | N = 197e | |||
| 1–6 | 31 | 15.7 | 4.1 | 2.0–7.4 |
| 7–12 | 55 | 27.9 | 4.1 | 0.5–7.1 |
| 13–18 | 7 | 3.6 | 2.9 | 1.3–6.9 |
| 19–24 | 31 | 15.7 | 3.97 | 1.7–8.1 |
| 25–30 | 16 | 8.1 | 4.4a | 0.4–8.9a |
| 31–36 | 31 | 15.7 | 4.8 | 0.6–9.4 |
| 37–42 | 15 | 7.6 | 5.8 | 1.4–7.8 |
| 43–46 | 11 | 5.6 | 5.6 | 2.8–5.9 |
Abbreviations: Ct, cycle threshold; NSCLC, non–small cell lung cancer.
a
One specimen (squamous cell carcinoma, stage IIIA) was excluded from the analysis due to an outlier ΔCt value of −7.2.
b
ΔCt results missing for 10 adenocarcinoma, 2 squamous cell carcinoma, 1 large-cell carcinoma, and 1 adenosquamous carcinoma specimen.
c
Stage I includes stage IA, stage II includes stages IIA and IIB, and stage III includes stage IIIA.
d
N = 194: tumor stage was unknown for 6 specimens.
e
N = 197: biopsy dates were missing for 3 specimens.
f
ΔCt value available from only 1 patient with adenosquamous carcinoma.